Shares of Esperion Therapeutics (NASDAQ:ESPR) decreased after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were down 72.12% over the past year to ($3.89), which missed the estimate of ($3.76).
Revenue of $9,638,000 up by 881.47% year over year, which missed the ...
Full story available on Benzinga.com